Results 211 to 220 of about 568,926 (318)
Antimalarial drug resistance and drug discovery: learning from the past to innovate the future. [PDF]
Theodoridis L, Carvalho TG.
europepmc +1 more source
Closing down on glyphosate inhibition—with a new structure for drug discovery
Murtaza F. Alibhai, William C. Stallings
openalex +1 more source
Cleavable N‐terminal Thioredoxin fusion enabled soluble expression and purification of otherwise insoluble SARS‐CoV‐2 Nucleocapsid (N) protein. A four‐step purification strategy yielded highly homogeneous, RNA‐free N protein. Binding assays showed high RNA affinity (Kd ~ 28 nm). The study will facilitate high‐resolution structural studies of N protein,
Shweta Singh, Gagan D. Gupta
wiley +1 more source
The silkworm: A promising invertebrate diabetes model for natural drug discovery. [PDF]
Ma J, Li W.
europepmc +1 more source
Functional parameters of spermatozoa obtained by a new selection device
This study compares density gradient centrifugation and the LensHooke CA0™ device for sperm separation. DGC requires multiple steps, specialized equipment, and technical expertise. In contrast, the CA0 device offers key practical and methodological advantages, resulting in a faster, simpler, and more affordable sperm selection method.
Julio C. Chávez+8 more
wiley +1 more source
Quantum Mechanics in Drug Discovery: A Comprehensive Review of Methods, Applications, and Future Directions. [PDF]
Niazi SK.
europepmc +1 more source
Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity
This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang+6 more
wiley +1 more source
CPDP: Contrastive Protein-Drug Pre-Training for Novel Drug Discovery. [PDF]
Zhang S, Wang X, Li F, Peng S.
europepmc +1 more source
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash+6 more
wiley +1 more source